Twitter Facebook LinkedIn

Heat Biologics, Inc. Heat Biologics, Inc.

  • Home
  • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Pelican Therapeutics
    • Heat Biologics Mask
  • Technology
    • gp96 Platform
    • Pelican’s PTX-35 Co-stimulatory Antibody
  • Product Pipeline
    • Overview
    • HS-110
    • HS-130
    • COVID-19 Vaccine
    • PTX-35
    • Expanded Access
    • Scientific Publications
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
    • Corporate Presentation
  • News & Media
    • News Releases
    • Events
  • Careers
  • Contact

Scientific Publications

Product Pipeline

Product Pipeline

  • Overview
  • HS-110
  • HS-130
  • COVID-19 Vaccine
  • PTX-35
  • Expanded Access
  • Scientific Publications
The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting Poster, November 8, 2019; Treating Advanced Non-Small Lung Cancer (NSCLC) Patients After Checkpoint Inhibitor Treatment Failure With a Novel Combination of Viagenpumatucel-L (HS-110) Plus Nivolumab

The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting Poster, November 8, 2019; Treating Advanced Non-Small Lung Cancer (NSCLC) Patients After Checkpoint Inhibitor Treatment Failure With a Novel Combination of Viagenpumatucel-L (HS-110) Plus Nivolumab

The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting abstract, November 5, 2019

The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting abstract, November 5, 2019

2019 American Society of Clinical Oncology (ASCO) Annual Meeting poster, June 2, 2019

2019 American Society of Clinical Oncology (ASCO) Annual Meeting poster, June 2, 2019

American Association of Cancer Research (AACR) ComPACT preclinical poster, May 29, 2019

American Association of Cancer Research (AACR) ComPACT preclinical poster, May 29, 2019

2019 ASCO-SITC Clinical Immuno-Oncology Symposium Poster

2019 ASCO-SITC Clinical Immuno-Oncology Symposium Poster

Nature Biopharma, “Harnessing the Immune System to Turn Cold Tumors Hot”

Nature Biopharma, “Harnessing the Immune System to Turn Cold Tumors Hot”

Nature Biopharma, “Activating Antitumor Activity”

Nature Biopharma, “Activating Antitumor Activity”

Gp96-Ig/costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T cell Priming and Enhances Immunity, Memory, and Tumor Elimination Heat Biologics 2017

Gp96-Ig/costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T cell Priming and Enhances Immunity, Memory, and Tumor Elimination Heat Biologics 2017

Viagenpumatucel-L (HS-110) with Nivolumab in the Ongoing DURGA Trial Heat Biologics 2016

Viagenpumatucel-L (HS-110) with Nivolumab in the Ongoing DURGA Trial Heat Biologics 2016

Viagenpumatucel-L (HS-110) Bolsters Response to Nivolumab Therapy in Advanced Lung Adenocarcinoma: Preliminary Data From The DURGA Trial Heat Biologics 2016

Viagenpumatucel-L (HS-110) Bolsters Response to Nivolumab Therapy in Advanced Lung Adenocarcinoma: Preliminary Data From The DURGA Trial Heat Biologics 2016

RSS
  • « Previous
  • 1
  • 2
  • 3
  • Next »
© 2021 Heat Biologics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap LinkedIn